Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 4/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.39 |
| ▸ | MMP8 | P22894 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20565642 | 0.75 | CYP4F2 (0.39) | CYP4F2CYP4A11MMP8PKMKDM4E | |
| SCHEMBL20565196 | 0.75 | GRM2 (0.46) | CYP4F2CYP4A11MMP8ABCB11CYP1A2 | |
| SCHEMBL20565602 | 0.75 | GRM2 (0.35) | TSHRALDH1A1HIF1A | |
| SCHEMBL20564605 | 0.74 | ALOX15 (0.38) | CYP4F2CYP4A11MMP8PKMKDM4E | |
| SCHEMBL20565636 | 0.74 | PKM (0.39) | CYP4F2CYP4A11MMP8PKMKDM4E | |
| SCHEMBL20565188 | 0.72 | MMP8 (0.35) | CYP4F2CYP4A11MMP8PKMKDM4E | |
| SCHEMBL20564524 | 0.72 | MEN1 (0.41) | CYP4F2CYP4A11MMP8PKMKDM4E | |
| SCHEMBL20565023 | 0.72 | GAA (0.36) | CYP4F2CYP4A11MMP8PKMKDM4E | |
| SCHEMBL20565079 | 0.70 | CYP4F2 (0.37) | CYP4F2CYP4A11MMP8PKMKDM4E | |
| SCHEMBL20565153 | 0.69 | MAPT (0.38) | CYP4F2CYP4A11MMP8PKMKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119285572-A | Kinase inhibitors and uses thereof | 戴纳立制药公司 | 2025-01-10 | — | — | CN | disclosed |
| US-20250011338-A1 | Kinase Inhibitors and Uses Thereof | DENALI THERAPEUTICS INC. (US) | 2025-01-09 | — | — | US | disclosed |
| CN-119264073-A | Kinase inhibitors and uses thereof | 戴纳立制药公司 | 2025-01-07 | — | — | CN | disclosed |
| US-12129263-B2 | Kinase inhibitors and uses thereof | DENALI THERAPEUTICS INC. (US) | 2024-10-29 | — | — | US | disclosed |
| CN-110913858-B | Kinase inhibitors and uses thereof | 戴纳立制药公司 | 2024-09-24 | — | — | CN | disclosed |
| US-20220041620-A1 | Kinase Inhibitors and Uses Thereof | DENALI THERAPEUTICS INC. (US) | 2022-02-10 | — | — | US | disclosed |
| US-11203600-B2 | Kinase inhibitors and uses thereof | DENALI THERAPEUTICS INC. (US) | 2021-12-21 | — | — | US | disclosed |
| EP-3624797-A1 | KINASE INHIBITORS AND USES THEREOF | Denali Therapeutics Inc. (US) | 2020-03-25 | — | — | EP | disclosed |
| CN-110913858-A | Kinase inhibitors and uses thereof | 戴纳立制药公司 | 2020-03-24 | — | — | CN | disclosed |
| US-20200087319-A1 | Kinase Inhibitors and Uses Thereof | DENALI THERAPEUTICS INC. (US) | 2020-03-19 | — | — | US | disclosed |
| WO-2018213632-A1 | KINASE INHIBITORS AND USES THEREOF | DENALI THERAPEUTICS INC. (US) | 2018-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011338-A1 | Kinase Inhibitors and Uses Thereof | MAP3K20, MAP3K6, MAP3K19 | CYP4F2 3293/4885CYP4A11 3699/4885MMP8 1725/4885 |
| US-20200087319-A1 | Kinase Inhibitors and Uses Thereof | MAP3K20, MAP3K6, MAP3K19 | CYP4F2 3293/4885CYP4A11 3699/4885MMP8 1725/4885 |
| US-11203600-B2 | Kinase inhibitors and uses thereof | MAP3K20, MAP3K6, MAP3K19 | CYP4F2 3293/4885CYP4A11 3699/4885MMP8 1725/4885 |
| US-20220041620-A1 | Kinase Inhibitors and Uses Thereof | MAP3K20, MAP3K6, MAP3K19 | CYP4F2 3293/4885CYP4A11 3699/4885MMP8 1725/4885 |
| US-12129263-B2 | Kinase inhibitors and uses thereof | MAP3K20, MAP3K6, MAP3K19 | CYP4F2 3293/4885CYP4A11 3699/4885MMP8 1725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.